Swiss Social Democrat’s for nationalization of Sandoz

INICIO/Noticias Farmacéuticas | Posted 19/11/2021 post-comment0 Post your comment

In November 2021, the Social Democratic party in Switzerland urged the government to buy Novartis AG’s generics and biosimilars unit, Sandoz. 

28 MD002360

It has been reported that Novartis is considering a possible sale or spinoff of its generics unit, Sandoz. This unit is estimated to be valued at over US$20 billion.

Samuel Bendahan, Vice President of the Social Democratic party in Switzerland stated that he believes the country’s purchase of Sandoz ‘would allow the construction of a company to serve the population, improve access to medicines, reduce future health risks and democratize research and development’.

The Sandoz generics drug unit has seen its global sales fall 4% to US$7.11 billion in the first nine months of 2021, and these were down 17% in the US. This is largely due to downward pricing pressure that has been particularly strong in the US, as well as rising competition in the generics market.

The Socials Democrats’ position to nationalize Sandoz takes into account the impact of the COVID-19 pandemic, which exposed how reliant nations in Europe are on both finished pharmaceuticals and raw materials from elsewhere in the world. The purchase or nationalization of Sandoz would secure generic drug supplies for the country.

Related articles
US Supreme Court rejects Enbrel patent challenge from Sandoz

AbbVie antitrust investigation and Sandoz biosimilar delay

Aurobindo/Sandoz deal falls through, biosimilars business transferred to subsidiary

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Regulación del registro de medicamentos biológicos en América Latina

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Regulación del registro de medicamentos biológicos en América Latina

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Spinoff updates: Merck’s Organon and Novartis’ Sandoz
24 AA011041
INICIO/Noticias Farmacéuticas Posted 26/11/2021
Ustekinumab biosimilars: new international biopharma agreements
Contract Tender V13H30
INICIO/Noticias Farmacéuticas Posted 12/11/2021
Biocon Biologics and Serum Institute Life Sciences partnership
64 MD002129
INICIO/Noticias Farmacéuticas Posted 12/11/2021
Agreement to produce similar biotherapeutic product in Turkey
12 AA010179
INICIO/Noticias Farmacéuticas Posted 05/11/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010